Inovio Pharmaceuticals, Inc. (INO)
NASDAQ: INO · Real-Time Price · USD
1.130
0.00 (0.00%)
At close: Apr 6, 2026, 4:00 PM EDT
1.140
+0.010 (0.88%)
Pre-market: Apr 7, 2026, 6:42 AM EDT
Inovio Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts that cover Inovio Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $6.75, which forecasts a 497.35% increase in the stock price over the next year. The lowest target is $3.00 and the highest is $13.
Price Target: $6.75 (+497.35%)
Analyst Consensus: Buy
* Price targets were last updated on Nov 14, 2025.
Analyst Ratings
The average analyst rating for Inovio Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Reiterates $5 → $6 | Buy | Reiterates | $5 → $6 | +430.97% | Nov 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $3 | Hold | Reiterates | $3 | +165.49% | Aug 14, 2025 |
| Piper Sandler | Piper Sandler | Buy Initiates $5 | Buy | Initiates | $5 | +342.48% | Jul 9, 2025 |
| RBC Capital | RBC Capital | Hold Reiterates $5 | Hold | Reiterates | $5 | +342.48% | May 14, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $15 → $13 | Buy | Maintains | $15 → $13 | +1,050.44% | May 14, 2025 |
Financial Forecast
Revenue This Year
16.01M
from 65.34K
Increased by 24,407.60%
Revenue Next Year
69.09M
from 16.01M
Increased by 331.40%
EPS This Year
-1.46
from -1.81
EPS Next Year
-0.19
from -1.46
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 43.6M | 128.5M | |||
| Avg | 16.0M | 69.1M | |||
| Low | n/a | 33.3M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 66,618.7% | 702.4% | |||
| Avg | 24,407.6% | 331.4% | |||
| Low | - | 108.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -1.11 | -0.18 | |||
| Avg | -1.46 | -0.19 | |||
| Low | -1.76 | -0.20 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.